Dr. Lorenzo Gianni - Oncologia Rimini
Dr. Lorenzo Gianni - Oncologia Rimini
Dr. Lorenzo Gianni - Oncologia Rimini
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
MO19391: ATHENA trial<br />
100<br />
Complete response<br />
Partial response<br />
80<br />
Response rate (%)<br />
60<br />
40<br />
20<br />
10<br />
52.3<br />
9.0<br />
43.3<br />
58.8<br />
6.4<br />
52.3<br />
36.4<br />
2.0<br />
34.3<br />
32.0<br />
10.0<br />
22.0<br />
47.9<br />
14.8<br />
33.1<br />
60.0<br />
8.8<br />
51.3<br />
50.0<br />
6.3<br />
43.8<br />
0<br />
Paclitaxel<br />
monoterapy<br />
(n=675)<br />
Docetaxel<br />
monoterapy<br />
(n=512)<br />
Capecitabine<br />
monoterapy<br />
(n=99)<br />
Vinorelbine<br />
monoterapy<br />
(n=50)<br />
Paclitaxel<br />
combination<br />
(n=142)<br />
Docetaxel<br />
combination<br />
(n=80)<br />
Non-taxane<br />
combination<br />
(n=48)<br />
a<br />
Tumor assessment performed by investigators according to standard clinical practice<br />
Pierga J, et al. ASCO 2009, #1033
Change language